Scholarlink

<p>Myeloproliferative neoplasms (MPNs) are classically attributed to somatic variants in <i>JAK2</i>, <i>CALR</i>, and <i>MPL</i>, with epidemiologic studies demonstrating an increased risk for MPNs within first-degree relatives. Germline variants associated with MPN predisposition include rare variants of low population frequency/high penetrance alleles, often in <i>JAK2</i>, resulting in non-clonal MPN-like disorders, including hereditary thrombocytosis (HT). The first activating germline <i>JAK2</i> variant encoding a residue other than V617F identified in association with a hereditary MPN-like syndrome was c.1691 G &gt; A, p.Arg564Gln (R564Q), a gain-of-function missense variant. Here, we present the cases of three unrelated individuals with HT and the germline <i>JAK2</i> R564Q variant, two of whom were tested in 2023, and received clinical reports classifying the variant as a variant of uncertain significance, and the third, tested more recently from a different laboratory, which classified the variant as likely pathogenic (LP). We propose that germline testing should be offered at minimum to MPN patients presenting at a young age, those with apparent familial clustering, and those with triple negative/idiopathic disease. These three cases provide additional segregation data that should sway consensus regarding the pathogenicity of this variant toward LP and resolve the conflicting classifications for this variant in ClinVar.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Germline JAK2 R564Q variants presenting as hereditary thrombocytosis: case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Stephanie Franco,
  • Kinga Krawiec,
  • Piotr Strzalka,
  • Lucy A. Godley

摘要

Myeloproliferative neoplasms (MPNs) are classically attributed to somatic variants in JAK2, CALR, and MPL, with epidemiologic studies demonstrating an increased risk for MPNs within first-degree relatives. Germline variants associated with MPN predisposition include rare variants of low population frequency/high penetrance alleles, often in JAK2, resulting in non-clonal MPN-like disorders, including hereditary thrombocytosis (HT). The first activating germline JAK2 variant encoding a residue other than V617F identified in association with a hereditary MPN-like syndrome was c.1691 G > A, p.Arg564Gln (R564Q), a gain-of-function missense variant. Here, we present the cases of three unrelated individuals with HT and the germline JAK2 R564Q variant, two of whom were tested in 2023, and received clinical reports classifying the variant as a variant of uncertain significance, and the third, tested more recently from a different laboratory, which classified the variant as likely pathogenic (LP). We propose that germline testing should be offered at minimum to MPN patients presenting at a young age, those with apparent familial clustering, and those with triple negative/idiopathic disease. These three cases provide additional segregation data that should sway consensus regarding the pathogenicity of this variant toward LP and resolve the conflicting classifications for this variant in ClinVar.